# OnCo record rejuv-tx-late-effects-overview (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/rejuv-tx-late-effects-overview/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "rejuv-tx-late-effects-overview" ;
  schema:name "Late effects after a stem cell transplant"@en ;
  schema:alternateName "transplant late effects"@en, "post-transplant survivorship"@en, "long-term complications of HSCT"@en ;
  schema:description "There are now around half a million people alive worldwide who have had a blood or marrow transplant. Most of them have at least one lasting health problem from it, and many have several. The list is long and reads heavily, but almost every item on it is either preventable or detectable early, which is the reason to know what is on it rather than to avoid knowing."@en ;
  schema:url <https://onco.cc/technologies/rejuv-tx-late-effects-overview/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation> ;
  schema:citation <https://doi.org/10.3324/haematol.2016.150250>, <https://doi.org/10.1016/j.bbmt.2011.12.519>, <https://doi.org/10.1182/bloodadvances.2018019117>, <https://doi.org/10.1016/j.bbmt.2014.02.012>, <https://doi.org/10.1182/blood-2008-05-158782> ;
  onco:status "established" ;
  onco:tag "rejuvenation", "survivorship", "transplant", "late-effects" ;
  onco:related <https://onco.cc/technologies/rejuv-tx-survival-after-transplant/>, <https://onco.cc/technologies/rejuv-tx-second-cancers/>, <https://onco.cc/technologies/rejuv-tx-iron-overload/>, <https://onco.cc/technologies/rejuv-tx-bone-eyes-kidneys-lungs/>, <https://onco.cc/technologies/rejuv-tx-endocrine-and-cardiometabolic/>, <https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/>, <https://onco.cc/technologies/gvhd-chronic-overview/>, <https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/>, <https://onco.cc/technologies/rejuv-tx-what-to-ask-for/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/total-body-irradiation/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/conditioning-regimen/>, <https://onco.cc/terms/quality-of-life/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> .